T2 Biosystems is developing next-generation medical diagnostic products using its proprietary detection technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to eliminate sample preparation and provide rapid, accurate and portable diagnostics for assays that cannot be performed in a decentralized setting.  T2 is a Flagship VentureLabs company.

Doug Levinson was founding CEO.  Harry Wilcox serves on the Board of Directors.